Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report
Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with...
Saved in:
Main Authors: | Arvin Pramudita, Cleopas M Rumende, Ardi Findyartini |
---|---|
Format: | Article |
Language: | English |
Published: |
Interna Publishing
2017-08-01
|
Series: | Acta Medica Indonesiana |
Subjects: | |
Online Access: | https://www.actamedindones.org/index.php/ijim/article/view/327 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fixed-dose combination antituberculosis therapy as a risk factor for tuberculosis recurrence: an evidence-based case report
by: Arvin Pramudita, et al.
Published: (2017-08-01) -
An overview of fixed-dose combinations of antihypertensive drugs in South Africa
by: Natalie Schellack, et al.
Published: (2014-07-01) -
Bioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects
by: A. L. Khokhlov, et al.
Published: (2022-05-01) -
From combined therapy to fixed-dose combinations
by: I. P. Kolos, et al.
Published: (2008-08-01) -
Therapy compliance and fixed-dose combinations in arterial hypertension treatment. Focus on a fixed-dose combination of felodipine and metoprolol
by: S. A. Shalnova, et al.
Published: (2009-12-01)